Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Isatuximab, lenalidomide, bortezomib and dexamethasone as induction therapy show...
Dr Elias Mai - University Hospital Heidelberg, Heidelberg, Germany
Isatuximab, lenalidomide, bortezomib and dexamethasone as induction therapy show a superior MRD negativity rate for newly diagnosed MM patients ( Dr Elias Mai - University Hospital Heidelberg, Heidelberg, Germany )
13 Jun 2022
The abscopal effect of radiotherapy and nivolumab in relapsed or refractory Hodg...
Dr Paul Bröckelmann - University of Cologne, Cologne, Germany
The abscopal effect of radiotherapy and nivolumab in relapsed or refractory Hodgkin lymphoma ( Dr Paul Bröckelmann - University of Cologne, Cologne, Germany )
13 Jun 2022
Targeted therapy combinations with venetoclax superior to chemoimmunotherapy in ...
Prof Barbara Eichhorst - The University of Cologne, Cologne, Germany
Targeted therapy combinations with venetoclax superior to chemoimmunotherapy in frontline CLL ( Prof Barbara Eichhorst - The University of Cologne, Cologne, Germany )
13 Jun 2022
A novel CAR-T cell therapy targeting BCMA is highly effective for patients with ...
Dr Carlos Fernández De Larrea - Hospital Clínic de Barcelona, Barcelona, Spain
A novel CAR-T cell therapy targeting BCMA is highly effective for patients with relapsed/refractory multiple myeloma ( Dr Carlos Fernández De Larrea - Hospital Clínic de Barcelona, Barcelona, Spain )
13 Jun 2022
A single dose of ctx001 shows promising efficacy and safety for TDT and severe S...
Prof Franco Locatelli - Sapienza, University of Rome, Rome, Italy
A single dose of ctx001 shows promising efficacy and safety for TDT and severe SCD ( Prof Franco Locatelli - Sapienza, University of Rome, Rome, Italy )
13 Jun 2022
Quizartinib improves overall survival in adult patients with FLT3-ITD+ acute mye...
Dr Harry Erba - The Duke Cancer Institue, Durham, USA
Quizartinib improves overall survival in adult patients with FLT3-ITD+ acute myeloid leukaemia ( Dr Harry Erba - The Duke Cancer Institue, Durham, USA )
13 Jun 2022
Treatment with decitabine resulted in a similar survival and fewer adverse event...
Prof Michael Lübbert - Universitätsklinikum Freiburg, Freiburg, Germany
Treatment with decitabine resulted in a similar survival and fewer adverse events compared with chemo in older patients with AML ( Prof Michael Lübbert - Universitätsklinikum Freiburg, Freiburg, Germany )
13 Jun 2022
Adagrasib shows CNS penetration and encouraging intracranial activity for KRASG1...
Dr Joshua Sabari - Perlmutter Cancer Center NYU Langone Health, New York, USA
Adagrasib shows CNS penetration and encouraging intracranial activity for KRASG12C-mutated NSCLC and active, untreated CNS metastases ( Dr Joshua Sabari - Perlmutter Cancer Center NYU Langone Health, New York, USA )
10 Jun 2022
Spotlight on global cancer control at ASCO 2022
Prof Eduardo Cazap - Editor-in-Chief, ecancer and SLACOM
Spotlight on global cancer control at ASCO 2022 ( Prof Eduardo Cazap - Editor-in-Chief, ecancer and SLACOM )
10 Jun 2022
UICC announces global coalition to increase access to essential cancer medicines...
Dr Cary Adams - Chief Executive Officer, Union for International Cancer Control
UICC announces global coalition to increase access to essential cancer medicines in low and lower middle-income countries ( Dr Cary Adams - Chief Executive Officer, Union for International Cancer Control )
9 Jun 2022
Comment: LUMINA results show that women with low levels of the Ki67 biomarker ca...
Dr Corey Wayne Speers - University of Michigan, Ann Arbor, USA
Comment: LUMINA results show that women with low levels of the Ki67 biomarker can avoid outcomes related to radiotherapy ( Dr Corey Wayne Speers - University of Michigan, Ann Arbor, USA )
9 Jun 2022
Biomarker guidance allows patients 55 or older with low-grade luminal A-type bre...
Dr Timothy J. Whelan - McMaster University, Ontario, Canada
Biomarker guidance allows patients 55 or older with low-grade luminal A-type breast cancer to avoid radiation therapy ( Dr Timothy J. Whelan - McMaster University, Ontario, Canada )
9 Jun 2022